Search for other works by this author on: ...

Treatment with a BRAF inhibitor of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation has an estimated 5-year survival rate of 34%, with 19% being progression free. To improve ...

其中，BRAF 激活突变在约 10% 的转移性结直肠癌中出现，这些患者对标准化疗反应不佳，预后较差。BRAF V600E 突变会激活丝裂原活化蛋白激酶（Mitogen-Activated Protein Kinase，MAPK）信号通路，这也成为了靶向治疗的重点目标。目前，BRAF（恩考芬尼 encorafenib）和表皮生长 ...

What is the best gaming mouse? That depends on your needs, but buying a quality rodent can revolutionize how it feels to interact with your gaming PC. A high-quality mouse with the features you ...

The cost-effectiveness agency has backed the combination of Braftovi (encorafenib) and Eli Lilly's Erbitux (cetuximab) as a second-line treatment option for BRAF V600E mutated mCRC after an ...

The poster will include clinical data as of an April 4, 2025 data cutoff from the Company’s ongoing Phase 1/2 clinical trial evaluating azenosertib in combination with encorafenib and cetuximab in ...

The poster will include clinical data as of an April 4, 2025 data cutoff from the Company's ongoing Phase 1/2 clinical trial evaluating azenosertib in combination with encorafenib and cetuximab in ...

Researchers have developed an innovative nano-immune agonist that significantly improves immunotherapy outcomes for melanoma—a highly aggressive and hard-to-treat form of skin cancer. The study ...

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at ...

Melanoma is a type of skin cancer. When it spreads to other places in your body, it's called metastatic, or advanced. If you have fair skin or you’ve spent lots of time in the sun, it’s a ...